S
Shuyang Zhu
Researcher at Renmin University of China
Publications - 5
Citations - 54
Shuyang Zhu is an academic researcher from Renmin University of China. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 15 citations.
Papers
More filters
Journal ArticleDOI
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Yuankai Shi,Gongyan Chen,Xinkang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shuyang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Cheng,Hui-fang Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,Fei Liu,Yong Jiang,Chuan Gu +21 more
TL;DR: Furmonertinib (AST2818) is an irreversible, selective, third-generation EGFR tyrosine-kinase inhibitor as discussed by the authors , which is a new potential treatment option for this population.
Proceedings ArticleDOI
Reference hijacking: patching, protecting and analyzing on unmodified and non-rooted android devices
TL;DR: Reference hijacking can substantially improve the practicability of many security enhancement efforts for Android, and is presented to address the problem of securing Android devices by introducing a specially designed reset procedure.
Journal ArticleDOI
Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR mutated non-small cell lung cancer: results from the FURLONG study.
Yuankai Shi,Gongyan Chen,Xinkang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shuyang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Chen,Hui-fang Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,Meilin Liu,Yong Jiang,Chuan Gu +21 more
TL;DR: In this article , the authors reported the CNS efficacy of furmonertinib compared with gefitinib in untreated EGFR-sensitizing mutation-positive NSCLC from the FURLONG study.
Journal ArticleDOI
A Study on the Impact of Pilot Free Trade Zones on Regional Technological Innovation and Spatial Spillover Effects
Li-Hui Wang,Shuyang Zhu +1 more
Journal ArticleDOI
Empagliflozin improves renal ischemia–reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK–OPA1 pathway promotion
Wenbo Yang,Xiaoli Li,Shuyang Zhu,Xiaopeng Zhang,Zixiong Huang,Biyue Yu,Chun-Ping Cui,Qian Wang +7 more
TL;DR: Wang et al. as mentioned in this paper showed that empagliflozin could prevent or alleviate renal ischemia-reperfusion injury and can be applied for preemptive administration in kidney transplantation.